~~<i id='6555765410'><strike id='6555765410'><tt id='6555765410'><pre id='6555765410'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：hotspot 2025-09-28 06:44:20 Page View：88372

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Bristol, Sangamo, Gilead, and more
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bayer'sU.S.president,SebastianGuth,emphasizedataninterviewattheSTATofficesinBostonthatthepharmacompa

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

AwatertaxiisseenontheChicagoRiverinChicago,Monday,July3,2023,adayafterheavyrainsfloodedChicagostreet

WSS

comprehensive

comprehensive

knowledge

explore

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather